Dose-Dependent Response to Cyclodextrin Infusion in a Rat Model of Verapamil Toxicity by Mottram, Allan R et al.
ORIGINAL RESEARCH
Dose-Dependent Response to Cyclodextrin Infusion in a Rat
Model of Verapamil Toxicity
Allan R. Mottram, MD*
Sean M. Bryant, MD
†
Steven E. Aks, DO
†
*University of Wisconsin School of Medicine and Public Health, Department of
Medicine, Madison, Wisconsin
†Cook County-Stroger Hospital, Department of Emergency Medicine, Chicago, Illinois
Supervising Section Editor: Brandon K. Wills, DO, MS
Submission history: Submitted December 30, 2010; Revision received March 2, 2011; Accepted March 21, 2011
Reprints available through open access at http://escholarship.org/uc/uciem_westjem
DOI: 10.5811/westjem.2011.3.6696
Introduction: Sulfobutylether-b-cyclodextrin (SBE-CD) is a pharmaceutical excipient known to bind
verapamil. Following intravenous administration, clearance of SBE-CD approximates glomerular
filtration rate. We hypothesized that infusion of SBE-CD would increase time to asystole in a rat model
of verapamil toxicity in a dose-dependent manner. The objective was to demonstrate the effect of a
range of SBE-CD concentrations in a rat model of verapamil toxicity.
Methods: Twenty-five Wistar rats were allocated to control or 1 of 4 intervention groups. All received
ketamine and diazepam anesthesia followed by verapamil infusion 32 mg/kg/h. The verapamil infusion
for the intervention groups was premixed with SBE-CD in a 1:1, 1:2, 1:4, or 1:8 molar ratio (verapamil to
SBE-CD). The control group infusion did not contain SBE-CD. Additional saline or water was added to
the infusion so that the total volume infused was the same across groups, and the osmolality was
maintained as close to physiologic as possible. Heart rate, respiratory rate, and temperature were
monitored. The primary endpoint was time to asystole.
Results: Verapamil coinfused with SBE-CD in a molar ratio of 1:4 resulted in prolonged time to
asystole compared to control (21.2 minutes vs 17.6 minutes, P , 0.05). There were no differences in
time to asystole between control and any other intervention group. There was no significant difference
in time to apnea between control and any intervention group. We assessed the effect of a range of
SBE-CD concentrations and identified 1 concentration that prolonged time to asystole. Mechanisms
that may explain this effect include optimal volume expansion with a hyperosmolar cyclodextrin
containing solution, complexation of verapamil within the hydrophobic cyclodextrin pore, and/or
complexation within micelle-like aggregates of cyclodextrin. However, mechanistic explanations for the
observed findings are speculative at this point.
Conclusion: The 1:4 verapamil to SBE-CD concentration was modestly effective with SBE-CD
concentrations above and below this range demonstrating nonstatistically significant improvements in
time to asystole. [West J Emerg Med. 2012;13(1):63–67.]
INTRODUCTION
Cyclodextrins are hydrophilic circular oligosaccharides of
various sizes containing a hydrophobic core. Lipophilic
molecules ﬁt into this hydrophobic core via nonionic bonds.
Altering the number of substituent groups to the outer ring of
the molecule signiﬁcantly changes its characteristics, including
its afﬁnity for complexing with drugs and its osmolarity. They
are widely used as pharmaceutical excipients to modify drug
solubility and stability.
1
Rather than improving drug delivery, we are interested in
the ability of cyclodextrins to enhance elimination of drug from
the body. This concept has proven feasible by the success of
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function as an intravenous reversal agent for rocuronium-
induced neuromuscular blockade following anesthesia.
2,3
Cyclodextrin molecules bind target drugs as a function of a
complexation constant.
4 Modiﬁcation of hydroxyl groups at the
outer ring of the hydrophobic core enhances this property. We
hypothesize that a favorable complexation constant, in addition
to an equilibrium inequality driving the formula towards
complexation, would allow binding and subsequent renal
elimination of the target drug.
Additional mechanisms may contribute to reversal of
toxicity. Micelle-like aggregates of cyclodextrin and drug-
cyclodextrin complexes may solublize lipophilic drugs.
5 By
creating an intravascular sink, the drug is prevented from
reaching the target organ. This is analogous to one proposed
mechanism for how intralipid infusion works in the setting of
bupivicaine, chlomipramine, and verapamil overdose.
6–8
Thestudyof cyclodextrins asantidotal therapydoes appear
in the literature. However, in contrast to the massive body of
work regarding pharmaceutical applications of cyclodextrins,
those regarding toxicologic applications are minimal. In-vitro
inactivation of sarin and soman, treatment of organophosphate
poisoning, and treatment of tunicaminyluracil toxicity is
reported.
9–12 The utility of cycodextrins as antidotes for the
most common cardiovascular and neurologic toxins has not
been evaluated.
The mechanism of drug reversal with intravenous
cyclodextrin infusion is sound and has proven efﬁcacy (ie,
sugammadex). As such, we sought to apply this concept to
models of drug toxicity which have shown signiﬁcant
morbidity and mortality and for which there are currently
limited therapeutic options. Potential drug candidates that ﬁt
these criteria included tricyclic antidepressants, propoxyphene,
calcium-channel antagonists, methamphetamine, and cocaine
among others. Selecting the ideal drug was aided by the
pharmaceutical chemistry literature. Verapamil is known to
complex wellwith sulfobutylether-b-cyclodextrin (SBE-CD) as
evidenced by bench work of verapamil enantiomeric
separation.
13,14
We have previously undertaken a study assessing the
utility of SBE-CD as antidotal therapy for verapamil-induced
cardiotoxicity in rats.
15 This was a rescue model that used the
same verapamil infusion as in the current study but a much
higher concentration of SBE-CD (1:16 molar ratio of verapamil
to cyclodextrin; 2.25 g/kg SBE-CD, 32 mg/kg/h verapamil).
This was administered as a bolus after the onset of
cardiotoxicity. Survival times were poorer in the cyclodextrin
group, which we proposed was primarily related to the
hyperosmolar load that accompanied the SBE-CD infusion
(1,025 mOsm/kg) in combination with verapamil-induced
cardiogenic shock. Additional confounding factors included
use of a rescue model that induced severe, refractory
cardiogenic shock prior to administration of our study drug,
and the occurrence of isoﬂurane induced apnea. As such, with
the current study, we used isoﬂurane for induction only,
maintained anesthesia with ketamine and diazepam, studied a
range of SBE-CD doses, and designed the study as a coinfusion
model rather than a rescue treatment model. The aim of this
study was to demonstrate the effect of a range of SBE-CD
concentrations in a rat model of verapamil toxicity.
METHODS
The study design was an unblinded controlled trial to
assess the effect of SBE-CD infusion in a rat model of
verapamil toxicity. The protocol was approved by the Animal
Care Committee at the University of Illinois Chicago. Male
Wistar rats (strain 003) weighing 224 to 301 g with indwelling
central venous femoral lines were purchased from Charles
River Laboratories and housed in single cages with free access
to food and water. Verapamil (2.5 mg/mL) was purchased from
Hospira Inc (Lake Forest, Illinois). A 30% w/v solution of
SBE-CD was prepared by dissolving 3 g dry SBE-CD in 100
mL of sterile water.
Preceding the experimental protocol, rats were allocated to
either the control group (n¼5) or 1 of 4 intervention groups (n
¼ 20). All rats underwent induction with 3% isoﬂurane via
enclosed box. They were then weighed, and anesthesia was
maintained with weight-based doses of ketamine (90 mg/kg
initial; 30 mg/kg supplemental) and diazepam (6 mg/kg initial;
2 mg/kg supplemental). Following this, they were placed on a
warming pad, and central venous lines were accessed for
administration of verapamil and SBE-CD via infusion pump
(Outlook 100 B.Braun, Bethlehem, Pennsylvania). Cardiac
monitoring electrodes were attached using alligator clips for
continuous monitoring (Escort II, Medical Data Electronics,
Arleta, California). The study protocol was initiated with 5
minutes of observation under anesthesia for all rats to ensure
stable respiratory rate and heart rate while maintaining
adequate depth of anesthesia. Following this, the verapamil and
SBE-CD infusion was initiated via central line. Verapamil (32
mg/kg/h) and SBE-CD (dose speciﬁed later) were compounded
into the same infusion bag. The drugs were diluted in normal
saline with additional saline and/or water added to the ﬁnal
concentrations as needed such that each subject would receive
the same volume infusion (total volume 18.6 ml/kg/h across all
groups) and the maximum osmolality would be limited. The
verapamil dose was selected as it is the established LD50. It
was efﬁcacious in our prior work and is only slightly less than
the dose established by Tebbutt et al (37.5 mg/kg/h) in a similar
rat model of verapamil toxicity.
15,7 The control group (group 1,
n¼5) received no SBE-CD. The 4 intervention groups received
verapamil and SBE-CD with the SBE-CD dose being 141 mg/
kg (group 2, n ¼5, 1:1 molar ratio of verapamil to SBE-CD),
282 mg/kg (group 3, n¼ 5, 1:2 molar ratio of verapamil to
SBE-CD), 564 mg/kg (group 4, n¼ 5, 1:4 molar ratio of
verapamil to SBE-CD), and 1,227 mg/kg (group 5, n¼ 5, 1:8
molar ratio of verapamil to SBE-CD). Infusate osmolality
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(1:8 infusion). Of note, SBE-CD is speciﬁed to have no effect
when administered to rats intravenously up to 2,000 mg/kg as
documented in commonly available materials safety data sheet
documents. Heart rate, respiratory rate, and temperature were
monitored from onset of anesthesia to asystole or 1 h. The
primary endpoint was time to asystole. Statistical analysis was
performed using SPSS Statistics 18.0 (SPSS Inc, Chicago,
Illinois). Data were analyzed for descriptive characteristics to
ensure it was normally distributed. Further analysis was via
paired t tests (discrete data) or one-way analysis of variance
with Bonferroni post-hoc t tests (continuous data) as
appropriate. Signiﬁcance was set at P , 0.05. Figures were
generated via Origin 7.5 (OriginLab Corporation,
Northampton, Massachusetts).
RESULTS
The baseline heart rate did not vary between control and
intervention groups over the ﬁrst 5 minutes of anesthesia, prior
to initiation of verapamil and SBE-CD infusion. The baseline
respiratory rate did vary between control and intervention
groups 2 (mean difference 18.2, 95% conﬁdence interval [CI]
4.7–31.7, P , 0.05) and 4 (mean difference 21.5, 95% CI 7.9–
35, P , 0.05) during this time period (Figure 1). There were no
signiﬁcant differences between control and intervention group
heart rate or respiratory rate during the drug infusion period
(Figure 1). Time to asystole was signiﬁcantly prolonged in
group 4 compared to control (21.2 vs 17.6 minutes, P , 0.05;
Figure 2). There were no other differences in time to asystole
between control and intervention groups (Figure 1). There was
no signiﬁcant difference in time to apnea between control and
any intervention group (Figure 1).
DISCUSSION
This study sought to identify a treatment beneﬁt deﬁned as
a prolonged time to asystole in verapamil cardiotoxic rats
coinfused with 141 mg/kg, 282 mg/kg, 564 mg/kg, or 1,227
mg/kg SBE-CD. These doses corresponded to a 1:1, 1:2, 1:4,
and 1:8 molar ratio of verapamil to cyclodextrin respectively.
The group infused with verapamil and SBE-CD in a 1:4 ratio
demonstrated prolonged time to asystole. It is possible that this
resulted from complexation of SBE-CD with verapamil, either
in the infusion bag or intravascularly, followed by increased
renal clearance, decreased tissue concentration, and reduced
toxicity. Complexation and sequestration of verapamil within
the hydrophobic cyclodextrin pore or within micelle-like
Figure 1. a, Time to asytole represented as absolute time 6 standard error (SE). The 1:4 group time to asystole (*) was significantly
prolonged compared to control (21.2 vs 17.6 minutes, P , 0.05). b, Time to apnea represented as absolute time 6 SE. There was no
significant difference between control and intervention groups. c, Baseline heart rate with 95% confidence interval (CI). There was no
significant difference between control and intervention groups. d, Baseline respiratory rate with 95% CI. There was significant variability
between control and intervention groups 2 (mean difference 18.2, 95% CI 4.7–31.7, P , 0.05) and 4 (mean difference 21.5, 95% CI 7.9–35,
P , 0.05).
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speculative at this point. An alternative explanation is that 18
ml/kg/h of hypertonic solution (315 mOsm/kg) provided an
ideal intravascular volume expansion, thus prolonging time to
asystole. Arguing against this alternative is the fact that the
solution administered to the 1:2 group was of the same
approximate osmolality (318 mOsm/kg) and did not show any
improvement in time to asystole.
LIMITATIONS
This project has several signiﬁcant limitations. Rats in
all groups experienced apnea very early in the course of the
protocol, despite the modiﬁcation of our protocol (ie, the use
of diazepam and ketamine). Ideally, they would have been
artiﬁcially ventilated to remove apnea as a confounding
variable. We were unable to perform invasive hemodynamic
monitoring. Such a capability would have allowed us to
better characterize the hemodynamic effects of SBE-CD.
Lastly, a small n, utilizing a small animal model, and lack of
clear mechanism of action limits the applicability of our
ﬁndings.
CONCLUSION
Inconclusion, this studyexplores theapplication of anovel
molecule to a challenging poisoning scenario. It demonstrated
prolonged time to asystole in rats infused with both verapamil
and SBE-CD compared to those infused with verapamil only.
While acknowledging its limitations, the study provides
support for further investigation of the use of cyclodextrins as
antidotes to drug toxicity.
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